Myra Vision Closes $17M In Series A Financing to Advance Glaucoma Device

Myra Vision announced the closing of its $17 million Series A financing, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors. In conjunction with the financing, the company has changed its name to Myra Vision Inc. from Myra Medical Inc.

“We are extremely pleased to close this round of financing with strong support from our investors, validating the clear unmet need for a treatment that safely and efficiently achieves high intraocular pressure (IOP) reduction for moderate to severe glaucoma patients,” Robert Chang, CEO of Myra Vision, said in a company news release. “Myra Vision’s innovative nanotechnology device is designed to allow physicians to safely maximize outflow to achieve optimized IOP reduction.”